This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Penumbra (PEN) Q4 Loss Narrower than Expected, Sales Top
by Zacks Equity Research
Penumbra, Inc. (PEN), that went public in Sep 2015, reported fourth-quarter 2016 loss of 8 cents per share, down from earnings of 5 cents per share year over year.
Can Penumbra (PEN) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Penumbra Inc. (PEN) is slated to release fourth-quarter 2016 results on Feb 28, after market close.
Can The Uptrend Continue for Penumbra (PEN)?
by Zacks Equity Research
Investors certainly have to be happy with Penumbra Inc (PEN) and its short term performance
Becton, Dickinson Commercially Launches Precise WTA Kits
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has made its Precise whole transcriptome analysis kits commercial available.
Baxter (BAX): Sluggish Macro Environment Mars Prospects
by Zacks Equity Research
On Jan 17, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.
Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Premier, Penumbra, DigitalGlobe and Sunrun
by Zacks Equity Research
Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Premier, Penumbra, DigitalGlobe and Sunrun
Medidata Solutions Clinical Cloud Gets Picked by Celgene
by Zacks Equity Research
Medidata Solutions Inc. (MDSO) recently announced that Celgene Corporation adopted Medidata Clinical Cloud.
Pacific Biosciences (PACB) to Sell 10 PacBio Sequel Systems
by Zacks Equity Research
Pacific Biosciences of California, Inc. (PACB), announced that it will sell 10 PacBio Sequel Systems to Novogene Bioinformatics Technology Company, Ltd.
Akers Biosciences (AKER) Closes Offering of 1.7M Shares
by Zacks Equity Research
Akers Biosciences, Inc. (AKER) recently announced the closing of a public offering of 1.7 million common shares.
Intuitive Surgical (ISRG) Expects Strong Revenues in Q4
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) announced that it expects fourth-quarter 2016 revenues of approximately $757 million.
Henry Schein Hurt by Higher Costs, Lacks Growth Drivers
by Zacks Equity Research
On Jan 10, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
Illumina and Bio-Rad Unveil Single-Cell Sequencing Solution
by Zacks Equity Research
Illumina, Inc. (ILMN) recently teamed up with Bio-Rad Laboratories (BIO) to launch the Illumina Bio-Rad Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference.
Fluidigm: Q4 Preliminary Results Fail to Cheer Investors
by Zacks Equity Research
The market is not really happy with South San Francisco, CA-based Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter and full-year 2016.
Ecolab (ECL) Acquires Abednego Environmental, Shares Gain
by Zacks Equity Research
In a bid to strengthen its water solution line of offerings, St. Paul, MN-based Ecolab Inc. (ECL) announced the acquisition of Abednego Environmental Services.
NuVasive at 52-Week High on Preliminary Results, MHLW Nod
by Zacks Equity Research
Share price of San Diego, CA-based NuVasive, Inc. (NUVA) scaled a new 52-week high of $71.03 on Jan 11, finally closing a tad lower at $70.7.
Luminex Projects Strong Q4 Revenues, Issues 2017 Guidance
by Zacks Equity Research
Luminex Corporation (LMNX) announced that it expects revenues in the fourth quarter of 2016 to be approximately $72 million and approximately $271 million for full-year 2016.
DexCom Looking Forward to Strong Revenues in Q4 and 2016
by Zacks Equity Research
DexCom, Inc. (DXCM), a renowned medical device company, reported that it expects preliminary, unaudited revenue of approximately $168 million for the fourth quarter ended Dec 31, 2016.
K2M Group Holdings (KTWO) in Focus: Stock Up 6.3%
by Zacks Equity Research
K2M Group Holdings, Inc. (KTWO) saw its shares rise above 6% in the last trading session.
Integra LifeSciences at 52-Week High on Deals, View Update
by Zacks Equity Research
Shares of Integra LifeSciences Holdings Corporation (IART), a global leader in medical technology, scaled a new 52-week high of $45.50 on Jan 10, closing a tad lower at $44.90.
Teleflex Launches LMA Gastro Airway, FDA Okays Arrow VPS
by Zacks Equity Research
Teleflex Inc. (TFX) recently announced the launch of LMA Gastro Airway with Cuff Pilot Technology and the receipt of 510(k) approval from the U.S. FDA for its Arrow VPS Rhythm device.
PerkinElmer (PKI) to Acquire India-Based Tulip Diagnostics
by Zacks Equity Research
PerkinElmer, Inc. (PKI) announced that it has entered into a definitive agreement to acquire Tulip Diagnostics Private Ltd.
Allscripts (MDRX) Q4 Bookings Likely to Hit Record Levels
by Zacks Equity Research
Allscripts Healthcare Solutions Inc. (MDRX) recently provided a bullish update on bookings alongside providing a number of financial updates on fourth quarter 2016.
Air Methods (AIRM): Winter Hits December Passenger Count
by Zacks Equity Research
Air Methods Corporation (AIRM), reported tepid preliminary patient transport and tourism passenger data for the month of Dec 2016.
AngioDynamics (ANGO) Beats Q2 Earnings, Lifts 2017 View
by Zacks Equity Research
AngioDynamics Inc. (ANGO) reported adjusted earnings of 19 cents per share in the second quarter of fiscal 2017 beating the Zacks Consensus Estimate by 3 cents.
Cerner Extends HNM Partnership with University of Missouri
by Zacks Equity Research
Cerner Corporation (CERN) and the University of Missouri Health Care announced that they have inked an agreement to extend their partnership.